Background
==========

Maintenance of body fluid volume and composition is essential for proper physiologic function in humans. Under normal conditions, the glomerular filtration rate of the two kidneys is 180 L day^-1^, and up to 90% of the filtrate is reabsorbed in the proximal tubule and descending limb of Henle\'s loop. The key hormone that regulates reabsorption is the antidiuretic hormone arginine vasopressin (AVP), which is secreted by the posterior pituitary in response to hypovolemia or hypernatremia \[[@B1]\]. AVP is transported by the blood to the kidney and binds to arginine vasopressin receptor 2 (AVPR2), leading to an increase in intracellular cAMP levels via the stimulatory Gs protein and adenylate cyclase, and to subsequent activation of protein kinase A and phosphorylation of aquaporin 2 (AQP2) water channels \[[@B2]\]. This process is necessary for proper reabsorption of the water in the principal cells of the collecting duct under the control of AVPR2 \[[@B3]\].

Congenital nephrogenic diabetes insipidus (NDI) is characterised by an inability to concentrate urine despite a normal or elevated plasma level of AVP. Two genes have been reported to be associated with NDI; X-linked *AVPR2*\[[@B4]\] and autosomal *AQP2*\[[@B5],[@B6]\]. The X-linked form of NDI is present in up to 90% of patients. Males with the disease-causing mutation are usually affected, and females heterozygous for the disease-causing mutation show various degrees of penetrance. Skewed X inactivation, which is preferential methylation of the normal allele of the *AVPR2*gene, can cause NDI in female heterozygotes \[[@B7]\].

To date, 178 *AVPR2*mutations, including 12 gross deletions \[[@B8]-[@B13]\], have been deposited in the BIOBASE database \[[@B14]\]. Large deletions that lead to complete loss of *AVPR2*and parts of the neighboring genes *ARHGAP4*\[[@B9],[@B11],[@B15]\] and *L1 cell adhesion molecule*(*L1CAM*) \[[@B16]\] have been reported. *ARHGAP4*, which is a member of the GTPase-activating protein family, is located telomeric to *AVPR2*and is expressed at a high level in hematopoietic cells. Recently, an NDI patient lacking *AVPR2*and all of *ARHGAP4*showed immunodeficiency characterised by a marked reduction in the number of circulating CD3+ cells and almost complete absence of CD8+ cells \[[@B17]\]. Herein, we describe a Japanese extended family with multiple NDI patients lacking the entire *AVPR2*locus and approximately half of *ARHGAP4*. Although none of the family members with NDI showed clinical signs of immunodeficiency, immunologic profiling showed slight abnormalities.

Results
=======

Mutation screening
------------------

Two patients (IV-2 and IV-4 in Figure [1](#F1){ref-type="fig"}) were admitted to the hospital at the age of 2 months with fever of unknown origin. NDI was diagnosed on the basis of clinical symptoms and laboratory findings (dehydration, hypernatremia, and hypotonic urine) and failure to increase urine osmolarity in response to 1-2esamino-8-D-arginine vasopressin (dDAVP) (Table [1](#T1){ref-type="table"}). The sister (IV-1) had no history of dehydration, but polyuria and polydipsia were noticed by her family members, and NDI was diagnosed on the basis of laboratory findings at the age of 2 years. None of the patients had any evidence of mental retardation or significant disease other than NDI. The pedigree of the Japanese NDI family is shown in Figure [1](#F1){ref-type="fig"}. Subjects indicated by a diagonal box (II-1, III-3, III-4, and II-4) have a history of polyuria and polydipsia since childhood, but NDI has not been diagnosed.

Genomic DNA from patients and available family members was subjected to PCR analysis. We first used the primer pair (additional file 1) that amplifies the genomic region between exon 1 and exon 3 of *AVPR2*, and no PCR products were amplified from DNA of IV-2 and IV-4 (data not shown). Therefore, we hypothesised that a large sequence around the *AVPR2*gene was deleted and performed PCR using the primers listed in the additional file 1. After narrowing the deleted region, we designed the primer pair AVPR2-GAP4 and obtained 386-bp PCR products for III-2, IV-2, III-3, III-4, II-4, III-10, and IV-4 (Figure [1](#F1){ref-type="fig"}), suggesting that these seven family members carry a large deletion that covers *AVPR2*and part of *ARHGAP4*. The AVPR2exon1 and AVPR2exon2 primer pairs amplify the genomic region of *AVPR2*exon 1 and exon 2, respectively. PCR was successful with DNAs from III-2, II-5, III-9, III-10, and IV-3, indicating that III-2 and III-10 are asymptomatic female carriers of the deletion. The physical map and identified deleted regions are shown in Figure [2](#F2){ref-type="fig"}. The deleted region includes all of the *AVPR2*gene locus and approximately half of the *ARHGAP4*gene. Sequencing of the 386-bp product from IV-4 revealed that the 5\' and 3\' break points were at positions 53,385 and 64,673 bp, respectively, relative to the published sequence (GenBank [U52112.2](U52112.2)) with an insertion of the GGGTACACCTC sequence in the break point (Figure [3](#F3){ref-type="fig"}).

![**a; The pedigree of the family with NDI**. A closed pox indicates affected members. Several family members (II-1, II-4, III-3, and III-4, indicated by a diagonal box) have histories of polyuria and polydipsia but have not been diagnosed with NDI. Family members marked with underlines are ones for PCR analysis. b; PCR amplification of the NDI family members. M, 100 bp marker, N, negative control. The regions amplified with the primer pairs (AVPR2exon1, AVPR2exon2, and AVPR2-GAP) are shown in Figure 2.](1471-2350-9-42-1){#F1}

![**The physical map and the deleted region in the Japanese NDI family**. 11,286 bp deletion was observed around *AVPR2*gene. Bold lines indicated amplified regions with primers (AVPR2-GAP, 386 bp with deletion, AVPR2exon1, expected product size 583 bp with no deletion, and AVPR2exon2, expected product size 600 bp with no deletion). 5\' deleted point occurred between *LCAP*and *AVPR2*, and 3\' deleted point was in the intron 10 of *ARHGAP4*.](1471-2350-9-42-2){#F2}

![**Sequence of deletion breakpoint in the NDI family**. 5\'and 3\' breakpoints at positions 53,385 and 64,673 bp, respectively, relative to the published sequence (GenBank [U52112.2](U52112.2)) are indicated with arrows. The sequence is shown in antisense orientation. There is an insertion of the \"GAGGTGTACCC\" sequence in the break point. Bold lines indicate palindromic sequence which could cause the interstitial deletion.](1471-2350-9-42-3){#F3}

###### 

basal urine osmolality and plasma osmolality

         Basal urine osmolality   Urine osmolality response to AVP or dDAVP   Plasma osmolality
  ------ ------------------------ ------------------------------------------- -------------------
  IV-1   102                      102→171                                     NA
  IV-2   30                       30→26                                       NA
  IV-4   100                      100→125                                     308

NA; data not available

Characteristics of immune function
----------------------------------

We evaluated the immune function of 3 family members lacking *ARHGAP4*. None of the patients in the present study had a clinical history of recurrent or opportunistic infections. Differential leukocyte counts were within normal range (data not shown), however, a reduction of CD4+ cells was observed in III-4, and a reduction of CD8+ cells was observed in IV-4 (Table [2](#T2){ref-type="table"}). Normal levels of CD3+CD4+CD45RA+ and CD3+CD4+CD45RO+ T cells were observed \[[@B18]\] and T cell receptor excision circles (TREC) of whole blood were within normal range in three patients tested. Serum IgG levels were relatively low in adult patients with slight reduction of CD19+ cells in III-3 and III-4. However differentiation of B cells using IgD, IgM and CD27 was not different from normal controls (data not shown).

###### 

Immunological evaluation of NDI patients

  ------------------------------------------------------------------------------------------------------------
                    III-3\        III-4\        IV-4\         Normal range (adult)   Normal range (children)
                    32 yr         29 yr         5 yr                                 
  ----------------- ------------- ------------- ------------- ---------------------- -------------------------
  CD3+ \[%\]        74.3          68.9          85.9          55--78                 55--83

  CD4+/CD3+ \[%\]   54.9          17.7          69.6          28--57                 27--53

  CD8+/CD3+ \[%\]   34.5          61.8          14            10--39                 19--34

  CD4/CD8           1.6           0.3           5             1.0--3.6               0.9--2.6

  CD19+ \[%\]       5.2           5.7           6.7           6--19                  10--31

                                                                                     

  IgG (mg/dl)       810.0         741.0         754.0         870--1700              600--1450

  IgA (mg/dl)       147.0         72.0          105.0         110--410               39--233

  IgM (mg/dl)       59.0          127.0         72.0          33--190                69--268

                                                                                     

  TREC/μgDNA        1.9 × 10^2^   2.8 × 10^2^   1.6 × 10^3^   3.4 ± 3.6 × 10^2^      3.5 ± 2.8 × 10^3^
  ------------------------------------------------------------------------------------------------------------

The normal range of the lymphocyte subpopulation was lower and the upper confidence limit at a confidence level of 0.95. The normal range of IgG, IgA, and IgM are calculated as mean - 2SD (lower) and mean + 2SD (upper). The normal range of TREC is expressed as mean ± SD.

Microarray analysis
-------------------

We examined the gene expression profiles of peripheral blood mononuclear cells (PBMCs) from subjects lacking *ARHGAP4*(III-3 and III-4) and 6 healthy male volunteers (age, 23--39 years). Transcripts satisfying all of the following criteria were identified as up- or down-regulated by microarray analysis: (1) transcripts that were expressed in at least 2 of 8 samples, (2) transcripts that showed statistically significant differences between subjects lacking *ARHGAP4*and, controls (Welch *t*-test, q \< 0.05; multiple tests were corrected by using the Benjamini and Hochberg false discovery rate \[[@B19]\]), and (3) transcripts that showed an average increase/decrease of more than 1.5-fold. Transcripts of *ARHGAP4*in PBMCs in III-3 and III-4 were absent, whereas strong expression was observed in all of the controls. Up- and down-regulated genes in PBMCs lacking *ARHGAP4*are listed in Table [3](#T3){ref-type="table"}. We hypothesized that lack of *ARHGAP4*could be compensated for by upregulation of other RhoGAP family members. Fifty-seven transcripts belonging to the RhoGAP family were included in the microarray analysis, and 25, including *ARHGAP4*were expressed in at least 2 of 8 samples. Expression levels of the transcripts other than *ARHGAP4*are shown in Table [4](#T4){ref-type="table"}. None of the transcripts of the RhoGAP family members were statistically significantly up/down regulated in the PBMCs.

###### 

Up/down regulated genes in PBMC lacking ARHGAP4

  Gene Name         Description                                                           ^a^Fold change   ^b^q value   ^c^Accession
  ----------------- --------------------------------------------------------------------- ---------------- ------------ ------------------------------
  Up-regulation                                                                                                         
                                                                                                                        
  PLK3              Polo-like kinase 3                                                    4.35             0.0402       [NM_004073](NM_004073)
  NHSL2             NHS-like 2                                                            2.38             0.0453       [NM_001013627](NM_001013627)
  PTAFR             Platelet-activating factor receptor                                   2.27             0.0288       [NM_000952](NM_000952)
  KLHL26            Kelch-like 26                                                         1.99             0.0272       [NM_018316](NM_018316)
  MAPKAPK2          Mitogen-activated protein kinase- activated protein kinase 2          1.96             0.0442       [NM_032960](NM_032960)
  CKAP4             Cytoskeleton-associated protein 4                                     1.85             0.0272       [NM_006825](NM_006825)
  CYB5R3            Cytochrome b5 reductase 3                                             1.82             0.0328       [NM_007326](NM_007326)
  ZC3H12A           Zinc finger CCCH-type containing                                      1.81             0.0428       [NM_025079](NM_025079)
  FURIN             Furin                                                                 1.79             0.0448       [NM_002569](NM_002569)
  GRN               Granulin                                                              1.76             0.0453       NM 002087
  PPOX              Protoporphyrinogen oxidase                                            1.75             0.0307       [NM_000309](NM_000309)
  NQO2              NAD(P)H dehydrogenase, quinone 2                                      1.74             0.0453       [NM_000904](NM_000904)
  DPH3              Diphthamide biosynthesis protein 3                                    1.70             0.0307       [NM_206831](NM_206831)
  PGD               Phosphogluconate dehydrogenase                                        1.68             0.00562      [NM_002631](NM_002631)
  RIPK5             Receptor interacting protein kinase 5                                 1.66             0.0386       [NM_015375](NM_015375)
  CD14              CD14 molecule                                                         1.62             0.0272       [NM_000591](NM_000591)
  PGD               Phosphogluconate dehydrogenase                                        1.57             0.0272       [NM_002631](NM_002631)
  Down-regulation                                                                                                       
  TUSC4             Tumor suppressor candidate 4                                          0.63             0.0453       [NM_006545](NM_006545)
  PLEKHG4           Pleckstrin homology domain containing, family G (with RhoGef          0.62             0.0272       [NM_015432](NM_015432)
  SFXN1             Sideroflexin 1                                                        0.61             0.0272       [NM_022754](NM_022754)
  GNRH1             Gonadotropin-releasing hormone 1                                      0.60             0.0328       [NM_000825](NM_000825)
  PPP1R3E           Protein phosphatase 1, regulatory                                     0.60             0.0383       [XM_940069](XM_940069)
  MC1R              Melanocortin 1 receptor                                               0.56             0.0272       [NM_002386](NM_002386)
  LRCH4             Leucine-rich repeats and calponin homology (CH) domain containing 4   0.55             0.0411       [NM_002319](NM_002319)
  LOC642787         Hypothetical protein LOC642787                                        0.44             0.0288       [XM_926202](XM_926202)
  SGPP2             Sphingosine-1-phosphate phosphotase                                   0.09             0.0307       [XM_938742](XM_938742)
  BNIPL             BCL2/adenovirus E1B 19 kD                                             0.06             0.0226       [NM_138278](NM_138278)
  ARHGAP4           Rho GTPase activating protein 4                                       0.00             0.000567     [NM_001666](NM_001666)

^a^The fold change was determined by calculating the ratio of global normalized signals from the PBMCs of NDI patients to those from the PBMCs of normal subjects. ^b^P values corrected by the Benjamini and Hochberg false discovery rate, and expressed as q values ^c^GenBank accession numbers

###### 

RhoGAP family gene expressions in PBMC lacking *ARHGAP4*

  Gene Name   Description                                              ^a^Fold change   ^b^q value   ^c^Accession
  ----------- -------------------------------------------------------- ---------------- ------------ ------------------------------
  ARHGAP1     Rho GTPase activating protein 1                          0.83             0.473        [NM_004308](NM_004308)
  ARHGAP9     Rho GTPase activating protein 9                          1.23             0.473        [NM_032496](NM_032496)
  ARHGAP10    Rho GTPase activating protein10                          1.01             0.914        [NM_024605](NM_024605)
  ARHGAP12    Rho GTPase activating protein 12                         1.03             0.655        [NM_018287](NM_018287)
  ARHGAP17    Rho GTPase activating protein 17                         0.67             0.473        [NM_018054](NM_018054)
  ARHGAP19    Rho GTPase activating protein 19                         1.16             0.473        [NM_032900](NM_032900)
  ARHGAP21    Rho GTPase activating protein 21                         0.98             0.655        [NM_020824](NM_020824)
  ARHGAP24    Rho GTPase activating protein 24                         1.33             0.891        [NM_001025616](NM_001025616)
  ARHGAP25    Rho GTPase activating protein 25                         0.90             0.565        [NM_001007231](NM_001007231)
  ARHGAP25    Rho GTPase activating protein 25                         0.93             0.83         NM 014882
  ARHGAP27    Rho GTPase activating protein 27                         0.81             0.473        [NM_199282](NM_199282)
  ARHGAP30    Rho GTPase activating protein 30                         1.16             0.473        [NM_001025598](NM_001025598)
  ARHGAP30    Rho GTPase activating protein 30                         0.86             0.565        [NM_181720](NM_181720)
  BM046       Rho GTPase activating protein 15                         0.92             0.655        NM 018460
  CDGAP       Cdc42 GTPase-activating protein                          0.86             0.891        NM 020754
  CENTD2      Centaurin, delta 2                                       1.26             0.473        [NM_139181](NM_139181)
  CENTD3      Centaurin, delta 3                                       1.12             0.655        [NM_022481](NM_022481)
  GMIP        GEM interacting protein                                  1.17             0.473        [NM_016573](NM_016573)
  MYO9B       Myosin IXB                                               1.20             0.473        [NM_004145](NM_004145)
  OCRL        Oculocerebrorenal syndrome of Lowe                       1.00             0.655        [NM_000276](NM_000276)
  PIK3R1      Phosphoinositide-3-kinase, regulatory                    0.94             0.571        [NM_181504](NM_181504)
  PIK3R2      Phosphoinositide-3-kinase, regulatory subunit 2 (beta)   0.86             0.655        [NM_005027](NM_005027)
  RACGAP1     Rac GTPase activating protein 1                          0.83             0.473        NM 013277
  RALBP1      RalA binding protein 1                                   0.84             0.565        [NM_006788](NM_006788)

^a^Fold change was determined by calculating the ratio of global normalized signals from PBMC of NDI patients to that of normal subjects. ^b^P values corrected by the Benjamini and Hochberg false discovery rate, and expressed as q values ^c^GenBank accession number

Discussion
==========

In this study, we identified an extended Japanese family with X-linked NDI whose affected and carrier members have an 11.2-kb deletion and 11-bp insertion that leads to complete loss of the *AVPR2*gene and part of the *ARHGAP4*gene.

X-linked congenital NDI is caused by loss of or decreased function of AVPR2, and large deletions that lead to complete loss of *AVPR2*and parts of the neighboring genes *ARHGAP4*and L1CAM \[[@B9],[@B11],[@B15]\] have been reported.*ARHGAP4*is expressed at high levels in hematopoietic cells. Because of the predominant expression pattern in hematopoietic cells, Schoneberg *et al*\[[@B11]\] performed immunologic analysis of blood from an NDI patient with complete loss of the *AVPR2*gene and most of *ARHGAP4*. They observed a slight reduction in numbers of CD4+ cells and normal white blood cell counts, proliferation, cytokine and immunoglobulin production, respiratory burst, and phagocytosis. In addition to the patients in the present study, five NDI patients with partial deletion of *ARHGAP4*have been reported \[[@B9],[@B11],[@B15]\], and none showed clinical signs of immunodeficiency. However, Broides *et al*. reported a pediatric NDI patient lacking *AVPR2*and all of *ARHGAP4*who showed immunodeficiency characterised by a marked reduction in the number of circulating CD3+ cells and an almost complete absence of CD8+ cells \[[@B17]\]. In this patient, the deleted region included 1.4 kb of intron 1, the first exon of *ARHGAP4*and a 2.8 kb sequence between *ARHGAP4*and *ARD1A*; this sequence is highly conserved across species, and Broides *et al*, speculated that this conserved region was the cause of the immunodeficiency phenotype observed in their patient. Hematologic tests of our patients showed a reduction of CD4+ cells in III-4, a reduction of CD8+ cells in IV-4, and a slight reduction of serum IgG levels in adult patients, but none of our patients showed susceptibility to infection. Taken together with the results of previous studies, our present results suggest that ARHGAP4 plays some role in lymphocyte differentiation, but does not cause the immunodeficiency phenotype. ARHGAP4 belongs to the RhoGAP family which enhances intrinsic GTPase activity. RhoGTPases are critical regulators of many cellular activities, such as motility and proliferation. We used the microarray technique to examine the possible effects on gene expression patterns in PBMCs by lacking *ARHGAP4*; several up-/down- regulated genes were identified. Our microarray study has several limitations. Firstly, it should be noted that microarray analysis is a screening method for detecting genes that may be regulated. Bosotti *et al*., reported that genes detected as differentially expressed by microarray platforms were also found to be differentially expressed by real-time quantitative PCR, although differences in the magnitudes of individual expression ratios were observed. \[[@B20]\] Secondly, PBMCs comprise a heterogeneous population of cells, and the possibility remains that the gene expression changes observed may merely reflect changes in the population of cells. However, because these patients lack *ARHGAP4*gene expression in all tissues and cells, it is likely that gene expression changes may be detected even in the heterogeneous cell populations. Gene expression profiling of PBMCs lacking *ARHGAP4*revealed that the expression of RhoGAP family genes was not influenced greatly by the lack of *ARHGAP4*, suggesting that loss of *ARHGAP4*expression is not compensated for by other gene family members.

In the present study, one girl (IV-1) was affected by NDI. Female carriers do not usually show symptoms of NDI as observed in IV-2 and IV-4, but a small proportion of female carriers develop varying degrees of polyuria and polydipsia that can be explained by skewed inactivation of the X chromosome containing the functional *AVPR2*allele. Although genetic testing has not been done for IV-1, it is very likely that she is a carrier of the deletion and that skewed X inactivation caused her symptoms.

A recent study showed that ARHGAP4 inhibits the migration of NIH/3T3 cells and the outgrowth of hippocampal axons and that the N-terminus and C-terminus of ARHGAP4 play different but essential roles in the potent inhibition of cell and axon motility \[[@B21]\]. The patients in the present study lack the C-terminus of ARHGAP4 (amino acids 515--965 according to the reference sequence NM_001666), but none of them showed clinical signs of immunodeficiencies or neurologic disorders. Further studies are needed to elucidate the role of ARHGAP4 in immune function and neuronal development.

Conclusion
==========

Our study indicated that loss of ARHGAP4 expression is not compensated for by other family members. ARHGAP4 may play some role in lymphocyte differentiation but partial loss of ARHGAP4 dose not result in clinical immunodeficiency.

Methods
=======

Patients and mutation detection
-------------------------------

The pedigree of the Japanese NDI family is shown in Figure [1](#F1){ref-type="fig"}. A full verbal and written explanation of the study was given to family members, and informed consent for the genetic study was obtained from members who participated in this study. Informed consent for the children was provided by their parents. This study was approved by the Committee of Ethics of the University of Tsukuba and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. DNA was extracted from peripheral blood leukocytes collected in ethylenediaminetetraacetic acid (EDTA). To identify the deleted region around *AVPR2*, primers were designed according to the published sequence (GenBank accession number [U52112.2](U52112.2)) with Primer3 software \[[@B22]\]. The primer sequences are listed in the additional file 1. Sequencing was performed with the Big Dye Terminator kit (Applied Biosystems, Foster City, California, USA) on an ABI PRISM 3100 DNA Sequencer (Applied Biosystems).

Immunological analysis
----------------------

Peripheral blood samples from III-3, III-4 and IV-4 in Figure [1](#F1){ref-type="fig"} were labeled with monoclonal antibodies according to the manufacturer\'s instructions and analysed with a FACSCalibur system (BD Biosciences, San Jose, California, USA). Monoclonal antibodies were purchased from BD Biosciences or Beckman-Coulter (Fullerton, California, USA). Quantification of TRECs was performed as described previously \[[@B23]\]. In brief, total DNA was isolated from 100 μl of peripheral blood with the use of a QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. The DNA concentration was determined with a GeneQuant pro system (GE Healthcare Bio-Sciences Corp. Piscataway, New Jersey, USA). Quantitative real-time polymerase chain reaction (PCR) for δRec-ψJα sjTRECs was performed with the following primers and probe: δRec primer, 5\'-TCGTGAGAACGGTGAATGAAG-3\', ψJα primer, 5\'-CCATGCTGACACC\'TCTGGTT-3\', and δRec probe, FAM-5\'-CACGGTGATGCATAGGCACCTGC-3\'-TAMRA. As an internal control, *RNase P*genes were amplified in each sample tested. In each experiment, serial dilutions (10^9^, 10^8^, 10^7^, 10^6^, 10^5^, 10^3^, 10^1^, and 10^0^) of the subcloned sjTREC-plasmid (pCR4-TOPO, Invitrogen Corp., Carlsbad, California, USA) and RNase P-plasmid were used as standards for absolute quantification of TRECs and RNase P copies. Each 20-μl reaction contained 1 μl DNA, and the final concentration of each component for TREC-PCR was as follows: 2× TaqMan Universal PCR Master Mix (Applied Biosystems), 500 nM of each primer, and 250 nM TaqMan probe. The final concentration of each component for RNase P-PCR was as follows: 2× TaqMan Universal PCR Master Mix and 20× TaqMan RNase P Primer Probe (VIC dye) Mix (Applied Biosystems). PCR conditions were 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Experiments were performed and analysed with an ABI PRISM 7300 Sequence Detection System (Applied Biosystems). Results were extrapolated to the number of TRECs per μg DNA and that of RNase P copies per μg DNA. To confirm that the DNA yields were adequately purified, TRECs were also normalised to copies of RNase P genomic DNA.

Microarray analysis
-------------------

PBMCs from III-3, III-4, and six healthy male volunteers (age, 23--39 years) were purified with a Ficoll-Paque™ gradient (GE Healthcare Bio-Sciences Corp.). RNA from PBMCs was extracted with an RNeasy Mini Kit (Qiagen) according to the manufacturer\'s instructions. cRNA was synthesized with an Illumina^®^RNA Amplification Kit (Ambion, Austin, Texas, USA) according to the manufacturer\'s instructions. In brief, 500 ng total RNA from PBMCs was reverse transcribed to synthesise first and second strand cDNA and purified on spin columns, and in vitro transcription was performed to synthesise biotin-labeled cRNA. A total of 1500 ng biotin-labelled cRNA was hybridised to a Sentrix Human-6 Expression BeadChip version 2 (Illumina, San Diego, California, USA) at 55°C for 18 hours. The hybridised BeadChip was washed and labelled with streptavidin-Cy3 (GE Healthcare Bio-Sciences Corp.) and then scanned with the Illumina BeadStation 500 System (Illumina). The scanned image was imported into BeadStudio (Illumina) for analysis. Forty-eight thousand transcripts representing six whole-genome samples can be analysed on a single BeadChip. We included at least two technical replicates (i.e., the same cRNA samples) for each BeadChip.

Background-corrected values for each probe on the BeadChip array were extracted using BeadStudio version 1.5.1.3 (Illumina). This is based on the average of negative control genes and is called the method of background normalization by Illumina. These extracted values were exported to the software GeneSpring version 7.3.1 (Silicon Genetics, Redwood, CA), and per chip and per gene normalization were performed. The statistical significance of the microarray data was calculated using the Welch *t*-test, and multiple tests were corrected by the Benjamini and Hochberg false discovery rate \[[@B19]\]. Significance was defined as q \< 0.05.
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